Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune SA (NASDAQ: ACIU) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Prof. Andrea Pfeifer will lead a fireside chat discussing the company’s corporate strategy, focusing on precision medicine and ongoing clinical trials, including the Lauriet Phase 2 trial of semorinemab for Alzheimer’s disease. The fireside chat will be available on-demand during the conference and later on AC Immune’s website. The company continues to advance its pipeline aimed at treating neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced that its Co-Founder and CEO, Andrea Pfeifer, received the SEF.WomenAward for CEO of the Year at the Swiss Economic Forum on September 2, 2021. The award acknowledges the exemplary entrepreneurial achievements of women. Pfeifer emphasized the importance of recognizing talent in the field of neurodegenerative diseases, stating that their work, alongside pharmaceutical partners, aims to advance a diversified pipeline targeting these critical health challenges. AC Immune focuses on personalized medicine for conditions like Alzheimer’s and Parkinson’s.
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical firm, has announced its participation in several upcoming virtual investor conferences. Key events include the Citi’s 16th Annual BioPharma Virtual Conference on September 8 and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 10. During these conferences, CEO Prof. Andrea Pfeifer will present the company’s corporate strategy and discuss its clinical-stage vaccine programs targeting neurodegenerative diseases. A webcast of the presentations will be available on AC Immune’s website.
AC Immune SA (NASDAQ: ACIU) announced that the Phase 2 Lauriet trial of semorinemab in mild-to-moderate Alzheimer's disease met one co-primary endpoint, ADAS-Cog11, showing a 43.6% reduction in cognitive decline compared to placebo (p<0.0025). However, the second endpoint, ADCS-ADL, was not met, and no significant effects were seen on other cognitive measures. The safety profile of semorinemab was consistent with prior studies. Genentech will continue the open label portion of the trial, with top-line results scheduled for presentation at the CTAD conference in November 2021.
AC Immune SA (NASDAQ: ACIU) announced a strategic acquisition of the PD01 vaccine candidate for Parkinson's disease and secured investments from prominent backers of BioNTech SE. With a robust cash position of CHF 199.1 million, the company is financed through at least Q1 2024. Recent clinical results for ACI-24 demonstrated immunogenicity in Down syndrome-related Alzheimer’s, while the Phase 1b/2a anti-pTau trial has been expanded with promising interim results. However, the company reported a net loss of CHF 19.1 million for Q2 2021.
AC Immune announced promising Phase 1b results for the anti-Abeta vaccine ACI-24 in adults with Down syndrome, correlating immune response with target engagement. The study found ACI-24 to be safe, with no serious adverse events reported. Additionally, the administration of ACI-24 resulted in increased plasma Abeta levels. The company plans further development of ACI-24 and aims to shift towards earlier treatment of Alzheimer’s disease (AD). ACI-12589, a diagnostic for Parkinson’s disease, is also being presented, with further advancements expected in the pipeline.
AC Immune (NASDAQ: ACIU) announces the acquisition of Affiris' portfolio, including the clinically-validated active vaccine candidate for Parkinson's disease, PD01, in an all-stock transaction valued at USD 58.7 million. This acquisition, supplemented by a USD 25 million private placement led by Athos Service GmbH, enhances AC Immune's cash position and accelerates therapeutic development. AC Immune plans to launch a Phase 2 study of the vaccine targeting alpha-synuclein in Parkinson’s patients, combining their expertise in vaccine development with Affiris' innovative technology.
AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting, where shareholders re-elected the Board of Directors, including Douglas Williams as Chairman. The company remains focused on advancing its Alzheimer’s disease vaccine programs despite the challenges posed by COVID-19. These vaccines target key proteins related to the disease, positioning AC Immune as a potential leader in the field. All AGM resolutions were approved, and the meeting complied with COVID-19 regulations.
AC Immune SA (NASDAQ: ACIU) recently reported significant developments regarding its vaccine candidate, ACI-24, for Alzheimer's disease. The Phase 2 interim analysis confirmed a strong safety profile without any CNS inflammation or adverse events. Notably, non-human primate studies showed that the optimized ACI-24 formulation generates a robust antibody response against neurotoxic pyroglutamate Abeta, surpassing earlier formulations. The company plans to file an Investigational New Drug (IND) application by the end of 2021 and aims to enter Phase 2 trials for Down syndrome-related Alzheimer's as early as 2022/23.
AC Immune SA (NASDAQ: ACIU) announced its participation in the UBS Global Healthcare Virtual Conference on May 26, 2021, and the Jefferies Virtual Healthcare Conference from June 2-4, 2021. CEO Prof. Andrea Pfeifer will present the company’s strategy and Alzheimer’s disease vaccine programs targeting phospho-Tau and Abeta. Webcasts of the events will be available on AC Immune’s website. The company focuses on precision medicine for neurodegenerative diseases, holding a diversified pipeline with six clinical trials ongoing.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
